Pfizer/Merck KGaA’s Bavencio Fails in Gastric Cancer Study
Pfizer, Inc. PFE and its Germany-based partner Merck KGaA MKGAF announced that a phase III study evaluating their key pipeline candidate, avelumab, for the treatment of gastric cancer in the third-line setting, failed to meet the primary endpoint. The JAVELIN Gastric 300 trial study evaluated avelumab monotherapy for the treatment of unresectable, recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients whose disease progressed following two prior therapeutic regimens, regardless of PD-L1 expression […]